A prospective assessment of variables contributing to reduced relative dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.

被引：0
|
作者：
Shayne, M
Culakova, E
Wolff, D
Poniewierski, M
Lyman, GH
Dale, DC
Crawford, J
机构：
[1] Univ Rochester, Rochester, NY USA
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] Duke Univ, Med Ctr, Durham, NC USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S110 / S110
页数：1
相关论文
共 50 条
  • [1] Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
    Michelle Shayne
    Jeffrey Crawford
    David C. Dale
    Eva Culakova
    Gary H. Lyman
    Breast Cancer Research and Treatment, 2006, 100 : 255 - 262
  • [2] Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
    Shayne, Michelle
    Crawford, Jeffrey
    Dale, David C.
    Culakova, Eva
    Lyman, Gary H.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 255 - 262
  • [3] Predictors of reduced relative dose intensity (RDI) in patients with early-stage breast cancer (ESBC) receiving adjuvant chemotherapy (CT).
    Lyman, GH
    Crawford, J
    Dale, DC
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S49 - S49
  • [4] Factors associated with reduced dose intensity in patients receiving adjuvant chemotherapy for early-stage breast cancer (ESBC).
    Lyman, GH
    Wolff, DA
    Culakova, E
    Poniewierski, A
    Dale, DC
    Crawford, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S60 - S60
  • [5] A prospective risk model for neutropenic complications in early-stage breast cancer patients receiving adjuvant chemotherapy.
    Lyman, GH
    Kuderer, NM
    Shayne, M
    Dale, DC
    Wolff, D
    Culakova, E
    Poniewierski, MS
    Crawford, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S125 - S126
  • [6] Prospective validation of a risk model for first cycle neutropenic complications in early-stage breast cancer patients receiving adjuvant chemotherapy.
    Lyman, G. H.
    Kuderer, N. M.
    Crawford, J.
    Wolff, D. A.
    Culakova, E.
    Poniewierski, M. S.
    Dale, D. C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S283 - S284
  • [7] Factors associated with decreased relative dose intensity in older adults with early-stage breast cancer receiving chemotherapy
    Sedrak, Mina S.
    Sun, Can-Lan
    Magnuson, Allison
    Muss, Hyman
    Freedman, Rachel
    Gross, Cary P.
    Tew, William P.
    Klepin, Heidi
    Wildes, Tanya M.
    Dotan, Efrat
    O'Connor, Tracey
    Cohen, Harvey J.
    Kim, Heeyoung
    Katheria, Vani
    Jayani, Reena
    Arsenyan, Anait
    Levi, Abrahm
    Charles, Kemeberly
    Hurria, Arti
    Dale, William
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Dose delays, dose reductions, and relative dose intensity in early stage breast cancer patients receiving (neo) adjuvant chemotherapy in community oncology practices
    Favret, A. M.
    Li, X.
    Denduluri, N.
    Morrow, P. K.
    Bhor, M.
    Barron, R. L.
    Dhanda, R.
    Langeberg, W. J.
    Saravanan, S.
    Girardi, V.
    Lyman, G. H.
    CANCER RESEARCH, 2013, 73
  • [9] Baseline MUGA scans for patients with early-stage breast cancer receiving adjuvant chemotherapy
    Jeyakumar, A. S.
    Dipenta, J.
    Snow, S. L.
    Rayson, D.
    Thompson, K.
    Theriault, C.
    Younis, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Time to first febrile neutropenia among early stage breast cancer patients receiving adjuvant chemotherapy.
    Scott, SD
    Chrischilles, EA
    Link, BK
    Delgado, DJ
    Fridman, M
    Lyman, GH
    PHARMACOTHERAPY, 2003, 23 (03): : 406 - 406
12345